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Glioblastoma multiforme (GBM) is an aggressive form of brain cancer that originates 
from glial cells, which make up the supportive tissue surrounding neurons. Temozolomide 
(TMZ) is the current chemotherapeutic drug administered to treat GBM as it works to inhibit the 
growth of the cancer cells. This research study focused on developing a method for synthesizing 
novel hybrid compounds that combines TMZ with various fatty acids known to have anticancer 
properties, forming a series of imide compounds with potential chemotherapeutic effects. Before 
synthesizing the compounds, various methods for synthesizing an imide from a primary amide 
were tested to ensure that TMZ and fatty acids would successfully react with each other to form 
the novel hybrid compounds. Once the novel hybrid compounds are synthesized, they will be 

















 Glioblastoma multiforme (GBM) is a type of brain cancer known as an astrocytoma, as it 
originates from glial cells supporting neurons. Because of its aggressive and invasive nature, it is 
classified as a grade IV glioma, the most severe form of brain cancer (Thakkar et al., 2014). 
While GBM has a relatively low incidence rate of around 10 cases per 100,000 population, it is 
the most common type of brain cancer as it is found in about 60% of adults with a form of the 
disease. Patients with GBM are not expected to live long after diagnosis, with the average life 
expectancy being 15 months (Hanif et al., 2017; Rock et al., 2012). The shortened lifespan is 
partly due to the difficulty of detecting and diagnosing the disease in its early stages since some 
of the symptoms, such as headaches and seizures, are common and typically attributed to other 
neurological conditions (Jovčevska et al., 2013). Removing the tumor safely and entirely also 
presents a challenge as it can grow rapidly and uncontrollably throughout the central nervous 
system (CNS) (Liu and Mischel, 2017). Although GBM is a rare disease, its severity has made it 
a global health concern and increases the need to find a cure.  
 While there is currently no cure for GBM, there are treatment options available to help 
prolong the lives of individuals with the disease. Surgery is primarily conducted to remove as 
much of the tumor as possible. However, because the tumor invades large portions of the brain, 
removing it entirely risks negatively affecting neurologic activity; because of this, surgery is not 
the only treatment administered to patients with GBM (Yong and Lonser, 2012). Following 
surgery, radiation and chemotherapy are frequently used to minimize the size and growth of the 
tumor. In combination with radiation, patients are typically given an oral medication known as 
Temozolomide (TMZ), which is currently the standard chemotherapeutic drug for treating GBM 
(Yin et al., 2013; Wesolowski et al., 2010). This particular drug works as an alkylating agent, 
meaning that it can bind to the DNA of the glioblastoma cells, preventing the strands from 
 
 
forming the complete double helix structure and ultimately inhibiting cell division and growth. 
TMZ is also able to pass through the blood-brain barrier (BBB), a selectively permeable 
membrane that allows certain drugs to enter the brain and attack cancer cells (Agarwala and 
Kirkwood, 2000; Sarkaria et al., 2018). These characteristics of TMZ have made it the optimal 
chemotherapeutic drug to treat GBM for the time being.  
 While TMZ is currently the most successful chemotherapeutic drug against GBM, 
glioblastoma cells tend to develop a resistance to the compound. About half of the patients who 
receive TMZ are not receptive to the drug for this reason. The resistance is due to the expression 
of an enzyme found in glioblastoma cells called O6-methylguanine methyltransferase (MGMT). 
This protein, when expressed, repairs O6-methylguanine lesions, the areas where TMZ has 
blocked DNA formation by binding to the guanine bases of the strands (Chen et al., 2018). 
Currently, there is no other chemotherapeutic drug as potent as TMZ to treat GBM, so 
overcoming this resistance has become an area of focus to find a more effective treatment or cure 
for the disease (Jiapaer et al., 2018).  
 In an attempt to overcome the resistance of glioblastoma cells to TMZ, we worked to 
synthesize novel hybrid compounds that retain the anticancer properties of TMZ but also 
increase the efficacy of the drug with the help of another biologically active compound. Previous 
research done in Dr. Desmond Murray’s lab involved synthesizing various types of novel hybrid 
compounds including arylidene heterocycles and arylidene pyrazolones, some of which 
successfully decreased the viability of glioblastoma cells and others that had no significant effect  
(Flores, 2020; Hiramoto, 2020; Deonarine, 2020). A potential new class of novel hybrid 
compounds containing TMZ is hypothesized to have some anticancer activity considering the 
effect TMZ has on glioblastoma cells. The compounds specific to this study are known as novel 
temozolomide-fatty acid imide hybrid compounds. Fatty acids have been studied extensively for 
 
 
their biological properties such as antibacterial, antifungal, and anticancer activity. In 
chemotherapy, hybrid compounds containing fatty acids have been known to work well in 
treating various types of cancer since they increase the cytotoxicity of the compounds, making 
them more effective for suppressing the growth of the tumor. Previous research concluded that 
the fatty acids with the strongest anticancer effect are those with saturated, short-carbon chains 
(<10 carbons) and polyunsaturated, long-carbon chains (Jozwiaka et al., 2020); these types of 
fatty acids were taken into consideration when choosing the compounds for this study. Because 
both TMZ and fatty acids are known to have anticancer properties, we believe that combining 
them will potentially create more effective drugs than TMZ alone.  
The combination of TMZ and fatty acids has not been widely studied, but there are a few 
experiments where cancer cells were exposed to a mixture of the two compounds. An experiment 
done by Maor et. al. (2018) studied the anticancer activity of TMZ and various fatty acids (2-
hydroxyoleic acid [2-OHOA], Gamma-Linoleic acid [GLA], and Fish oil [FISH]) on 
glioblastoma, colon cancer, and endothelial cells. Unfortunately, physically combining the two 
compounds did produce an antagonistic effect; it was found that fatty acids could inhibit the 
cytotoxicity of TMZ and vice versa, especially for fatty acids such as GLA and 2-OHOA. 
In another experiment done by Ryu et al. (2012), TMZ was combined with valproic acid 
(VPA), a fatty acid used as a drug for certain health conditions such as seizures, bipolar disorder, 
and migraines. Contrary to Maor et al. (2018), the results showed that this combination of TMZ 
and VPA did have anticancer effects, as it helped inhibit MGMT expression in the glioblastoma 
cells, both in vivo and in vitro. Like the experiment mentioned previously, TMZ and the fatty 
acid were physically combined by simply mixing the two compounds. There are no known 
studies that chemically combine the two compounds to form a hybrid compound. This concept 
 
 
may provide a solution to the antagonism described by Maor et al. (2018) and hopefully work as 
well as the experiment by Ryu et al. (2012).  
When TMZ is combined with fatty acids, we believe that the general structure of the 
novel hybrid compounds will contain an imide (Figure 1). Imides and imide derivatives are 
another group of compounds known to have anticancer properties, including cytotoxic effects 
and the ability to influence DNA binding, like TMZ (Tumiatti et al., 2009). Because imides are 
known to have anticancer properties, this functional group is thought to also contribute to the 
efficacy of the novel hybrid compounds. While imide synthesis is a well-studied area of research, 
there is not much literature on producing an imide from a primary amide, which is a functional 
group found on the structure of TMZ (Figure 2). In one research study, Schnyder and Indolese 
(2002) developed a method that involved combining primary amides such as formamide, 
acetamide, and benzamide with aryl bromides through the process of carbonylation using carbon 
monoxide; however, such reaction conditions were not possible in our lab. Thus, we needed to 
develop a new method to synthesize the imide and ensure that the novel hybrid compounds will 
form.  
There were two main aims for this research project: 1) to develop a method for 
synthesizing an imide from a primary amide and 2) to use the new method to generate a series of 
novel temozolomide-fatty acid imide hybrid compounds. Unfortunately, because of the time 
constraint on the project, I was not able to synthesize the novel hybrid compounds, but it will be 
done in the future as a continuation of this study. Once the compounds have been synthesized, 
they will be tested on glioblastoma cells to determine their anticancer activity, if any, and be 






 The first step of this experiment was to develop a method for synthesizing an imide from 
a primary amide to ensure that the reaction between TMZ and fatty acids would be successful. 
Because TMZ and fatty acids were both limited in the lab and fairly expensive for small 
amounts, similar compounds were used for most of the trials to confirm the hypothesis that an 
imide would form. With the guidance of Dr. Murray, certain variables were modified to 
determine the best reaction conditions; a total of seven variables were tested for each reaction – a 
primary amide, an aryl or acyl halide to mimic the fatty acid, a catalyst to promote the reaction, a 
base to allow the formation of the imide, a solvent, reaction time, and reaction temperature. Each 
trial was essentially organized into three steps – Reaction, Isolation, and Analysis. While many 
of the reactions seemed to produce the desired compound, one of the more promising methods 
for synthesizing an imide was used for Reactions #4 and #7, where 4-methoxybenzamide was the 
primary amide and valeryl chloride acted as the fatty acid.  
Reaction 
The first step was to prepare the reaction mixture in a round bottom flask (RBF). The 
reagents were added in the following order: acetonitrile for the solvent, potassium carbonate for 
the catalyst, N,N-diisopropylethylamine (Hünig’s base), 4-methoxybenzamide, and lastly, 
valeryl chloride dissolved in acetonitrile, which was added slowly to the reaction mixture using a 
syringe. The reaction was stirred for three hours in an ice bath. After the three hours, the mixture 
was poured into a beaker containing ice and 1M HCl to neutralize the mixture and form a 
precipitate which was expected to be the solid product. This mixture was then left overnight to 




The following day, the product was extracted from the rest of the reaction mixture using 
fresh ethyl acetate. The organic layer from the extraction, which contained the product, was dried 
using anhydrous sodium sulfate to remove any water that may have mixed with the organic layer. 
The product was then isolated by filtering out the anhydrous sodium sulfate and using a rotary 
evaporator to remove the ethyl acetate. In an attempt to fully dry the product, it was placed on a 
vacuum overnight.  
Analysis 
The product was analyzed in two ways: by calculating the percent yield (how much 
product formed) and using Nuclear Magnetic Resonance (NMR) Spectroscopy, which helps 
identify the compound based on the presence and location of hydrogens in the structure.  
Results 
 We completed a total of ten trials with several variations made to determine the best 
reaction conditions for synthesizing the imide (Figure 3). Table 1 provides a summary of the 
percent yield and NMR results for each product. Among the 10 trials, we tested four sets of 
starting materials with three primary amides and two halide compounds; the reactions are 
illustrated in Figures 4-7.  Figures 8-12 provide the NMR spectra for the starting materials and 
Figures 13-22 show the NMR spectra for the products.  
Reaction #1 
 The starting materials for this reaction were 4-methoxybenzamide (primary amide) and 
methyl 4-chlorobenzoate (fatty acid); the proposed reaction is illustrated in Figure 4. In addition 
to the starting materials, the following reagents were added to a round bottom flask: 
dimethylformamide (DMF) for the solvent, lithium hydride for the catalyst, and t-butyl alcohol 
for the base. The reaction mixture was then refluxed, which involved heating the mixture for 
three hours. To form the solid, I poured the reaction mixture into a beaker containing ice and 1M 
 
 
HCl and left it overnight. The next day, to isolate the product, the mixture was filtered using a 
vacuum filter. Once the product was completely dry, it was ready for analysis with NMR and 
calculating the percent yield.  
 The product of this reaction was a white and chalky powder. After analyzing the product, 
we determined that it was not the compound that we expected from the reaction. The percent 
yield was 55.4%. In the NMR spectrum, only a few of the necessary peaks were present, 
indicating that the desired compound did not form.  
 Reaction #2 
 For this trial, we repeated the same procedure that was used for Product #1, with the only 
change being the reaction time – instead of a 3-hour reflux, the reaction ran for 24 hours to see if 
more time would allow the reaction to take place. However, we determined that increasing the 
reaction time from 3 hours did not make a significant difference. Like the previous trial, the 
obtained product was white and chalky. Upon analysis, the percent yield was 43.0% and the 
NMR spectrum again did not show all the peaks for the product we expected to obtain.  
Reaction #3 
 The primary amide for this trial remained the same, but we used valeryl chloride instead 
of methyl 4-chlorobenzoate to act as the fatty acid (Figure 5). The following reagents were also 
added to a round bottom flask: acetonitrile (solvent), potassium carbonate (catalyst), and 
diisopropylethylamine (base). The valeryl chloride was first dissolved in acetonitrile before 
slowly being added to the reaction mixture. The mixture was then stirred for 90 minutes on an 
ice bath to observe the effect of colder temperatures on the reaction. Like the previous trials, the 
mixture was added to a beaker with ice and 1M HCl to form a precipitate and left overnight. The 
product, however, was not solid and had to be extracted using ethyl acetate. To remove the ethyl 
 
 
acetate and obtain the isolated product, the reaction was placed on a rotary evaporator then left 
overnight on the vacuum to remove any excess liquid.  
 The product from this reaction was orange and had some crystallized solid, which was 
different from previous trials. Although the product was left overnight on the vacuum, it did not 
completely dry. The percent yield was 84.7%  and the NMR spectrum showed that the desired 
product may be present among several extra peaks.   
Reaction #4 
 The reaction for this trial was the same as it was for Reaction #3, with the only change 
being an increase in reaction time for 90 minutes to 3 hours. Like the previous trial, the product 
was orange and contained both solid and liquid. The percent yield was slightly higher at 91.2%. 
The NMR spectrum looked very similar to the one for Product #3, as the product was present, 
but there was still a number of extra peaks.  
Reaction #5  
 The purpose of this trial was to test the effect of using different bases. This procedure 
repeated Reaction #4, but diisopropylethylamine was replaced with triethylamine. The product 
was a white, crystallized solid, which was a new observation.  The percent yield was 20.7%. The 
NMR spectrum was cleaner than the spectra for Products #3 and #4, with fewer extra peaks, 
although the peaks we expected to see were much weaker, specifically, those representing the 
hydrogen atoms on the carbon chain from valeryl chloride, found between 0 and 3.0 ppm.  
Reaction #6 
 Like the previous trial, we were working to determine the best base for the reaction. 
Instead of using triethylamine, we used 1,8-Diazabicyclo [5.4.0]undec-7-ene, commonly known 
as DBU.  Like Product #5, this product was white and crystallized. The percent yield was 28.3%. 
 
 
The NMR spectrum did indicate that the peaks for the desired product were present along with 
many extra peaks.  
Reaction #7 
 Based on the results from Reactions #4 and #5, we determined that 
diisopropylethylamine was the best base for the reaction as we had higher percent yields and 
more promising NMR spectra for both. For consistency purposes, this trial was a repeat of the 
fourth trial. Like Product #4, the product was orange and crystallized with some liquid 
remaining. The percent yield for this product was 78.0%. The NMR spectrum again showed 
multiple extra peaks, however, the desired compound was present in the product. We did notice 
at this time that some of the extra peaks may suggest that some starting materials (4-
methoxybenzamide and valeryl chloride) remained after the reaction, as there were duplicate 
peaks in the regions that indicated the presence of the product.  
Reaction #8 
 This trial continued to test the effect of using stronger bases. In addition to 
diisopropylethylamine, 3 drops of DMF were added to the reaction mixture. This new step was 
tested based on a graduate student’s current work in Dr. Murray’s lab, which also involves 
finding an effective method for synthesizing an imide from a primary amide. In addition to 
incorporating DMF, there were some other variations – the solvent was changed from 
acetonitrile to dichloromethane and, due to availability, 4-methoxybenzamide was replaced with 
4-fluorobenzamide, which has a similar structure (Figure 6). The product had the same physical 
appearance as Products #3, #4, and #7. The percent yield was 31.9% and NMR showed that the 






 Although the previous reaction had a low percent yield, we decided to continue with the 
same conditions using DMF since the imide still formed. Because we were getting the desired 
product and there was not much time left to conduct this research, we replaced the benzamide 
with TMZ to see if we could still obtain the imide compound using the reaction from the 
previous trial (Figure 7). The product was yellow and had a larger amount of liquid than the 
crystallized solid. The percent yield was 25.8%. NMR, unfortunately, showed that the reaction 
was not successful as there were some peaks missing from the spectrum.  
Reaction #10 
 To increase the amount of product, the moles of the limiting reagents (starting materials) 
were multiplied by three. The product looked very different from the others as it was yellow with 
a paste-like consistency. The percent yield was 39.1%. Like Product #9, the NMR spectrum did 
not show all the desired peaks, indicating that the reaction was not successful.  
Discussion 
 Based on the results, there is still quite a bit of work that needs to be done before 
synthesizing the novel temozolomide-fatty acid imide hybrid compounds. Out of the ten trials, 
six of the products contained the predicted imide compound. However, there was an issue with 
low percent yields for many of the products. The true reason for the low percent yields is 
unknown, although one contributing factor could be the loss of product as the reaction mixture 
was transferred to several vessels such as round bottom flasks, funnels, and beakers within one 
trial. In an attempt to increase the percent yield, we tried testing the effect of various bases on the 
reaction. Increasing the strength of the base was believed to allow more of the starting materials 
to react and form more of the product. However, the results show that increasing the strength of 
the base yielded less product. The reactions with the highest percent yields used 
 
 
diisopropylethylamine alone as the base, which is not as strong as the other bases that were 
tested. This correlation is currently not well understood and will need to be analyzed further to 
increase product yield.  
 Another problem that we encountered in this study was the presence of extra peaks in the 
NMR spectra for all the products that contained the compound. As previously mentioned for 
Products #7 and #8, we noticed duplicate peaks in the areas of the spectra that represented the 
hydrogens in the benzene ring of the primary amide and those in the hydrocarbon chain of the 
valeryl chloride. As indicated by Dr. Murray, these peaks give reason to believe that the product 
also contained unreacted starting materials. While Product #7 had a much higher percent yield 
than #8, it is possible that even small amounts of the starting materials did not undergo the 
reaction and were detected by NMR Spectroscopy. The additional peaks throughout the spectra 
may also indicate the presence of impurities, which may have come from the environment or 
simply remaining reagents from the reaction, similar to the starting materials. To resolve the 
issue with extra NMR peaks, one of the next steps in this study would be to develop a method for 
purifying the products.  
 It was also observed after performing the ten experiments that all the products 
synthesized using Hünig’s base had some liquid remaining, whereas the others were completely 
dry. It is possible that the liquid is not a part of the compound and is contributing to higher 
percent yields and extra NMR peaks. While the reason for the difference in the appearance of the 
products is not yet understood, we have decided that another step for this study is to try to 
remove the liquid. In the first two reactions, lithium hydride was used but was later replaced with 
potassium carbonate to see test the effect of a different catalyst. While potassium carbonate 
seemed to work well, using lithium hydride again may help remove the liquid as it works to 
absorb excess water, indicated by the first two products that were synthesized.  
 
 
 Although we determined that the best reaction conditions out of the 10 trials were for 
Products #4 and #7 and many of the products contained the imide compound, more time needs to 
be spent improving the methodology. We believe that both solvents tested, acetonitrile and 
dichloromethane, worked well in the formation of the imide. Regarding the reaction time and 
temperature, we found that stirring the mixture in an ice bath for three hours worked the best 
compared to heating the mixture and letting the reaction run for 90 minutes or 24 hours. 
However, as previously mentioned, the base and catalyst need to be further studied to optimize 
the methodology. Another variable that may need to be tested in the future is the primary amide. 
When using 4-methoxybenzamide and 4-fluorobenzamide as the primary amides, the formation 
of the imide was successful. However, when TMZ was used, the imide was not present in the 
product. The reason for this change is unclear and will need to be further analyzed before 
continuing the attempt to form the imide using TMZ.  
Although we are still in the beginning stages of this study, we still have a contribution to 
the development of a method for imide synthesis from a primary amide. There are elements in 
the tested methods that have shown promise and others that have not. Scientists can use the 
information in future studies to consider what may or may not work well in their experiments. 
Once a method has been developed and works well to create a series of novel hybrid compounds 
with TMZ and fatty acids, the compounds can then be tested on glioblastoma cells. Based on 
previous research in collaboration with Dr. Denise Smith in the Biology Department, the method 
for testing the anticancer properties of the novel hybrid compounds will involve exposing the 
glioblastoma cells to various concentrations of the compounds in a 12-well cell viability assay to 
determine the lethal concentration at which 50% or more of the cells die as a result of the 
exposure, a value known as the LC50 (Hiramoto, 2020). This will determine if the compound is 
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Figure 1. Proposed Reaction Between Temozolomide (left) and Fatty Acids (general structure in 
the middle). The reaction is believed to form an imide (circled on the right), a functional group 
characterized by the two carbonyl groups and NH group in the middle. The “R” represents the 
various hydrocarbon chains of fatty acids. When TMZ and the fatty acid combine to form the 












Figure 2. Primary Amide in Temozolomide. The primary amide functional group is 




















Figure 3. Products Obtained from the Ten Trials (labeled #1-10 from left to right). Products #5, 
#7, #8, and #9 have been dissolved in ethanol to easily transfer the product from the round 





















Figure 4. Reaction between 4-methoxybenzamide (left) and Methyl 4-chlorobenzoate (middle). 
This reaction was used for Products #1 and #2. Not pictured – excess CH3OH is also produced 





Figure 5. Reaction between 4-methoxybenzamide (left) and valeryl chloride (middle). This 
reaction was used for Products #3 through #7. Not pictured – excess HCl is also produced when 






Figure 6. Reaction between 4-fluorobenzamide (left) and valeryl (middle). This reaction was 





















Figure 7. Reaction between Temozolomide (TMZ) (left) and valeryl chloride (middle). This 
reaction was used to produce Products #9 and #10. Not pictured – excess HCl is also produced 




Table 1. Percent Yield and NMR Results 























8 4-fluorobenzamide/     
Valeryl chloride 
31.9 Present 
9 TMZ/Valeryl chloride 
 
25.8 Absent  































































































































































































































































































































































































































































































































































































































Figure 22. NMR Spectrum for Product #10.  
